Poly Pid Ltd - Understand $pypd stock

$PYPD Market Cap: $24.15 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$24.70M

TTM

Current Assets

$9.778M

Q2 2024

Current Liabilities

$10.29M

Q2 2024

Current Ratio

95.06%

Q2 2024

Total Assets

$19.53M

Q2 2024

Total Liabilities

$17.93M

Q2 2024

Book Value

$1.601M

Q2 2024

Cash

$3.076M

Q2 2024

P/E

-0.9779

Nov 15, 2024 EST

Free Cash Flow

-$17.47M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Revenue		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Selling, General & Admin	$6.719M	$10.90M	$12.59M	$9.320M	$4.480M	$5.810M	$4.060M	$2.550M	$2.930M	$940.0K	$410.0K
YoY Change	-38.36%	-13.44%	35.11%	108.04%	-22.89%	43.1%	59.22%	-12.97%		129.27%
% of Gross Profit
Research & Development	$16.15M	$27.99M	$30.55M	$16.95M	$14.08M	$12.55M	$9.740M	$7.710M	$5.630M	$2.640M	$1.380M
YoY Change	-42.31%	-8.39%	80.25%	20.38%	12.19%	28.85%	26.33%	36.94%		91.3%
% of Gross Profit
Depreciation & Amortization	$1.822M	$1.721M	$1.118M	$1.010M	$950.0K	$410.0K	$210.0K	$130.0K	$110.0K	$70.00K	$60.00K
YoY Change	5.87%	53.94%	10.69%	6.32%	131.71%	95.24%	61.54%	18.18%		16.67%
% of Gross Profit
Operating Expenses	$22.87M	$27.99M	$43.15M	$26.27M	$18.56M	$18.36M	$13.80M	$10.26M	$8.570M	$3.580M	$1.790M
YoY Change	-18.3%	-35.13%	64.24%	41.54%	1.09%	33.04%	34.5%	19.72%		100.0%
Operating Profit	-$22.87M	-$38.89M	-$43.15M	-$26.27M
YoY Change	-41.2%	-9.87%	64.22%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Interest Expense	-$929.0K	$800.0K	$512.0K	$720.0K	$310.0K	-$150.0K	$110.0K	$150.0K	-$1.530M	-$20.00K	-$30.00K
YoY Change	-216.13%	56.25%	-28.89%	132.26%	-306.67%	-236.36%	-26.67%	-109.8%		-33.33%
% of Operating Profit
Other Income/Expense, Net	-$929.0K	-$540.0K	$32.00K	-$11.31M	$11.35M	$24.43M	-$40.80M	-$1.280M	$350.0K	-$290.0K	$30.00K
YoY Change	72.04%	-1787.5%	-100.28%	-199.65%	-53.54%	-159.88%	3087.5%	-465.71%		-1066.67%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Pretax Income	-$23.80M	$39.56M	-$42.60M	-$36.87M	-$6.910M	$5.920M	-$54.49M	-$11.39M	-$9.750M	-$3.880M	-$1.790M
YoY Change	-160.16%	-192.85%	15.54%	433.57%	-216.72%	-110.86%	378.4%	16.82%		116.76%
Income Tax	$69.00K	$129.0K			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income		0.33%				0.0%
Net Earnings	-$23.87M	-$39.56M	-$42.60M	-$36.87M	-$6.910M	$5.920M	-$54.49M	-$11.39M	-$9.750M	-$3.880M	-$1.790M
YoY Change	-39.67%	-7.15%	15.54%	433.57%	-216.72%	-110.86%	378.4%	16.82%		116.76%
Net Earnings / Revenue
Basic Earnings Per Share	$16.99	$2.04	$2.28	$4.48
Diluted Earnings Per Share	-$16.99	$2.04	-$2.276M	-$1.994M	-$405.3K	$347.2K	-$3.196M	-$668.0K	-$743.7K	-$414.5K	-$191.2K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Cash & Short-Term Investments	$5.309M	$12.59M	$32.20M	$44.48M	$26.61M	$7.330M	$17.94M	$17.75M	$1.680M	$1.260M	$980.0K
YoY Change	-57.85%	-60.89%	-27.6%	67.16%	263.03%	-59.14%	1.07%	956.55%		28.57%
Cash & Equivalents	$5.309M	$8.552M	$9.819M	$4.320M	$3.920M	$7.330M	$3.910M	$10.22M	$1.680M	$1.260M	$980.0K
Short-Term Investments	$0.00	$4.042M	$22.38M	$40.16M	$22.69M	$0.00	$14.03M	$7.530M	$0.00
Other Short-Term Assets	$758.0K	$1.361M	$2.012M	$2.720M	$610.0K	$480.0K	$340.0K	$290.0K	$100.0K	$190.0K	$40.00K
YoY Change	-44.31%	-32.36%	-26.03%	345.9%	27.08%	41.18%	17.24%	190.0%		375.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.067M	$14.19M	$34.81M	$47.20M	$27.40M	$8.030M	$18.73M	$18.25M	$1.910M	$1.600M	$1.180M
YoY Change	-57.26%	-59.23%	-26.25%	72.26%	241.22%	-57.13%	2.63%	855.5%		35.59%
Property, Plant & Equipment	$9.218M	$11.68M	$8.761M	$5.890M	$6.120M	$6.190M	$2.930M	$850.0K	$440.0K	$330.0K	$350.0K
YoY Change	-21.07%	33.3%	48.74%	-3.76%	-1.13%	111.26%	244.71%	93.18%		-5.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$87.00K	$99.00K	$663.0K	$22.76M	$230.0K	$260.0K	$1.330M	$140.0K	$140.0K	$30.00K	$10.00K
YoY Change	-12.12%	-85.07%	-97.09%	9795.65%	-11.54%	-80.45%	850.0%	0.0%		200.0%
Total Long-Term Assets	$9.305M	$11.78M	$9.424M	$28.65M	$6.350M	$6.450M	$4.250M	$990.0K	$570.0K	$360.0K	$370.0K
YoY Change	-20.99%	24.97%	-67.11%	351.18%	-1.55%	51.76%	329.29%	73.68%		-2.7%
Total Assets	$15.37M	$25.97M	$44.24M	$75.85M	$33.75M	$14.48M	$22.98M	$19.24M	$2.480M	$1.960M	$1.550M
YoY Change
Accounts Payable	$772.0K	$1.141M	$4.136M	$970.0K	$1.580M	$1.130M	$2.020M	$780.0K	$580.0K	$230.0K	$60.00K
YoY Change	-32.34%	-72.41%	326.39%	-38.61%	39.82%	-44.06%	158.97%	34.48%		283.33%
Accrued Expenses	$2.511M	$3.372M	$3.666M	$1.900M	$990.0K	$2.450M	$1.240M	$820.0K	$1.100M	$240.0K	$140.0K
YoY Change	-25.53%	-8.02%	92.95%	91.92%	-59.59%	97.58%	51.22%	-25.45%		71.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$4.024M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$4.003M
YoY Change
Total Short-Term Liabilities	$7.286M	$8.553M	$8.076M	$2.880M	$2.580M	$3.690M	$3.360M	$1.700M	$1.670M	$500.0K	$210.0K
YoY Change	-14.81%	5.91%	180.42%	11.63%	-30.08%	9.82%	97.65%	1.8%		138.1%
Long-Term Debt	$6.379M	$7.574M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$190.0K	$0.00	$0.00
YoY Change	-15.78%							-100.0%
Other Long-Term Liabilities	$3.803M	$4.015M	$199.0K	$190.0K	$12.49M	$23.16M	$48.28M	$7.470M	$840.0K	$830.0K	$120.0K
YoY Change	-5.28%	1917.59%	4.74%	-98.48%	-46.07%	-52.03%	546.32%	789.29%		591.67%
Total Long-Term Liabilities	$10.18M	$11.59M	$199.0K	$190.0K	$12.49M	$23.16M	$48.28M	$7.470M	$1.030M	$830.0K	$120.0K
YoY Change	-12.14%	5723.62%	4.74%	-98.48%	-46.07%	-52.03%	546.32%	625.24%		591.67%
Total Liabilities	$17.47M	$20.14M	$8.275M	$3.070M	$15.07M	$26.85M	$51.65M	$9.170M	$2.710M	$1.330M	$330.0K
YoY Change	-13.28%	143.41%	169.54%	-79.63%	-43.87%	-48.02%	463.25%	238.38%		303.03%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	1.404M shares	19.43M shares	18.72M shares	9.582M shares
Diluted Shares Outstanding	1.421M shares	19.43M shares	18.72M shares	9.582M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $24.152 Million

About PolyPid Ltd

PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Industry: Surgical & Medical Instruments & Apparatus Peers: Scinai Immunotherapeutics Ltd Mediwound Ltd PainReform Ltd Redhill Biopharma Ltd